Connecta Therapeutics Raises €3.1M for Fragile X Drug Development

CONNECTA Therapeutics, a clinical-stage biotech firm focused on central nervous system disorders, has successfully closed a €3.1 million funding round. The investment, aimed at advancing its lead candidate CTH120 for Fragile X Syndrome (FXS), was spearheaded by Clave Capital through its Innvierte Science Tech Clave Innohealth fund. This capital infusion underscores significant investor confidence in novel approaches to neurodevelopmental conditions.

The newly secured funds will primarily fuel the ongoing Phase IIa clinical trial of CTH120 in adult males with FXS. Preliminary results from this crucial study are anticipated by mid-2027. This trial, building upon promising preclinical data and a favorable Phase I safety profile, is designed to assess the drug's safety, tolerability, and efficacy. The study is being conducted across key research institutions, including the Hospital del Mar Research Institute (HMRIB) and the Institut de Recerca i Innovació Parc Taulí (I3PT), with support from the Centre for Genomic Regulation (CRG) for biomarker identification.

This financing round saw robust participation from existing investors, demonstrating continued commitment to CONNECTA's mission. Inveready, through its BIO Fund IV, alongside the CDTI Innvierte program and the Prous Institute for Biomedical Research, all reinvested, signaling strong belief in the company's scientific trajectory and management team. The involvement of these established life science investors highlights the potential of CTH120 as a first-in-class modulator of neuroplasticity.

Jordi Fàbrega, CEO of CONNECTA Therapeutics, emphasized the significance of this funding as a pivotal moment for the company. He expressed optimism that the upcoming Phase IIa data will validate CTH120's potential to address the underlying biological mechanisms of FXS, a rare disease with substantial unmet medical needs, and ultimately improve patient quality of life. The company is also preparing to explore CTH120's application in pediatric patients through the FRAXCURE project.

Ignacio Prieto Fernández, Associate Investor at Clave Capital, noted CONNECTA's innovative strategy for tackling neuroplasticity in FXS, supported by a clear clinical development plan and an experienced team. He stated that Clave Capital is eager to support the company in achieving its next critical milestones. As part of the agreement, Prieto Fernández will join CONNECTA's Board of Directors, representing Clave Capital.

Fragile X Syndrome, a leading inherited cause of intellectual disability and autism spectrum disorder, affects approximately 1 in 4,000 males and 1 in 8,000 females. The market for rare disease therapeutics is experiencing significant growth, driven by advancements in genetic understanding and targeted therapies. CONNECTA's focus on neuroplasticity offers a novel therapeutic avenue in a field where effective treatments are scarce, positioning CTH120 as a potentially transformative option.